FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND: Form 990, tax year 2022
View the entire original 990 at ProPublica ↗
- Organization
- FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND (EIN 98-0407553)
- Tax period
- 2022-01-01 to 2022-12-31
- Filed
- 2023-11-15
- IRS object ID
- 202343199349316034
- Schema version
- 2022v5.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2023-11-15T13:23:20-06:00 | ReturnTs |
| Tax Period End | 2022-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERNST & YOUNG US LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1 MANHATTAN WEST | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10001 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2022-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 980407553 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Foundation for Innovative New Diagnostics | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| In Care Of | % NORMA TORRES COO | InCareOfNm |
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 0000000000 | PhoneNum |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | Chemin des Mines 9 | AddressLine1Txt |
| City | GENEVA | CityNm |
| Country | SZ | CountryCd |
| Foreign Postal | 1202 | ForeignPostalCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | NORMA TORRES | PersonNm |
| Person Title | CHIEF OPER. OFFICER | PersonTitleTxt |
| Phone | 7325164200 | PhoneNum |
| Signature | 2023-11-15 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | NORMA | PersonFirstNm |
| Person Last | TORRES | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | YUCEN zhong | PreparerPersonNm |
| PTIN | P01593150 | PTIN |
| Phone | 2127736170 | PhoneNum |
| Preparation | 2023-11-15 | PreparationDt |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 3 | TrustedCustomerCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2022 | TaxYr |
| Build TS | 2023-04-26 12:10:37Z | BuildTS |
Form 990 IRS990
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FIND | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | NORMA TORRES | PrincipalOfficerNm |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | Chemin des Mines 9 | AddressLine1Txt |
| City | GENEVA | CityNm |
| Country | SZ | CountryCd |
| Foreign Postal | 1202 | ForeignPostalCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $144,248,069 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | www.finddx.org | WebsiteAddressTxt |
| Type Of Organization Assoc | Yes (X) | TypeOfOrganizationAssocInd |
| Formation | 2003 | FormationYr |
| Legal Domicile Country | SZ | LegalDomicileCountryCd |
| Activity Or Mission | The development and implementation of new, low cost diagnostics for infectious diseases for use in low- resource areas. | ActivityOrMissionDesc |
| Voting Members Governing Body | 10 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 10 | VotingMembersIndependentCnt |
| Total Employee | 132 | TotalEmployeeCnt |
| Total Volunteers | 6 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $108,984,293 | PYContributionsGrantsAmt |
| CY Contributions Grants | $142,991,509 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $624,209 | PYInvestmentIncomeAmt |
| CY Investment Income | $961,319 | CYInvestmentIncomeAmt |
| PY Other Revenue | $423,638 | PYOtherRevenueAmt |
| CY Other Revenue | $295,241 | CYOtherRevenueAmt |
| PY Total Revenue | $110,032,140 | PYTotalRevenueAmt |
| CY Total Revenue | $144,248,069 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $48,933,103 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $87,636,841 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $17,658,685 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $21,916,139 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $805,909 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $29,001,922 | PYOtherExpensesAmt |
| CY Other Expenses | $36,633,518 | CYOtherExpensesAmt |
| PY Total Expenses | $95,593,710 | PYTotalExpensesAmt |
| CY Total Expenses | $146,186,498 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $14,438,430 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$1,938,429 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $189,507,117 | TotalAssetsBOYAmt |
| Total Assets EOY | $137,542,319 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $167,462,799 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $115,874,802 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $22,044,318 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $21,667,517 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $103,061,587 | ExpenseAmt |
| Grant | $72,311,140 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | COVID-19 EXPENDITURE USD 103,061,587 FIND's 2022 COVID-19 activities addressed access inequities as well as diagnostics research and development (R&D). FIND led major advances in regional diagnostics manufacturing and evaluated more than 50 COVID-19 tests. Investments led directly to manufacturing capacity based in low- and middle-income countries (LMICs) of 60 million COVID-19 rapid tests (RDTs) and self-tests per month, available to LMICs at US$1-2 per test. FIND's technology transfer programmes enabled Diatropix (Senegal) to manufacture high-quality COVID-19 RDTs and break ground on a new facility for low-cost, high-volume manufacturing for RDTs of regional importance. FIND supported Premier Medical Corporation (India) to expand production capacity to 10 million RDTs/month under global access terms. FIND enabled WAMA Diagnstica (Brazil) in the end-to-end manufacture of RDTs from raw materials. FIND's support enabled Wondfo Biotech (China) and Viatris (South Africa) to achieve WHO Emergency Use Listing (EUL) for their COVID-19 RDTs. Additionally, FIND's provision of independent trial data supported the WHO Emergency Use Listing (EUL) of six COVID-19 tests in 2022, and a seventh in 2023. FIND's assessment of COVID-19 Ag RDT performance included test accuracy and the ability to detect new variants. These studies have now encompassed 54 Ag RDTs, including professional use and self-tests. FIND monitored and mapped both testing and sequencing capacity for COVID-19, as well as tracking the impact of new variants of concern on test performance. FIND supported decentralized community-based testing for COVID-19 and test-and-treat strategies. FIND also generated data that helped in-country policy reviews on the use of Ag RDTs in settings beyond those recommended in the WHO guidelines, including pharmacy channels and non-traditional settings such as taxi ranks. FIND supported the procurement of 1,889,144 diagnostic tests and related consumables, of which 1,853,854 were COVID-19 Ag RDTs, while supporting the introduction of their use in 26 countries. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $10,283,492 | ExpenseAmt |
| Grant | $3,528,906 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | Tuberculosis (TB) and hepatitis (HCV) EXPENDITURE USD 10,283,492 FIND initiated its first-ever comprehensive involvement of patients in study design, through the Unitaid-funded DriveDx4TB project to seek patient perspectives on novel sample types for TB diagnostics. In the recent development of a WHO target product profile (TPP) for TB, FIND developed an impact model that indicates that new point-of-care (POC) tests for TB that provide results to the patient during the same clinical visit would require minimum sensitivities of 59-70% and 65-71% for non-sputum and sputum samples, respectively, depending on the country and standard of care, to achieve comparable or better case detection than the current standard of care. To maximize value for money of newly developed TB diagnostics, FIND introduced evidence-based target pricing into the forthcoming TPP for TB diagnostics. This work provides a novel framework to guide the future development of TPPs for diagnostics. FIND supported 10 TB products (7 IVDs and 3 digital tools) across various stages of diagnostic product life cycle including 4 IVDs and 1 digital tool in the development phases. FIND also supported 3 HCV tests in the development phases. FIND led the development of targeted next-generation sequencing (tNGS) for use in patients with TB, and the data obtained from this three-country study form the backbone of a new WHO evidence review and guidelines for TB management. FIND identified and demonstrated lot-to-lot variability of the FujiLAM TB rapid test as an unanticipated outcome of a large, seven-country evaluation of the test's accuracy, supporting the WHO decision to cancel a policy review; FIND supported FujiFilm in conducting a root cause analysis and planning a redesigned test. An existing digital global good, developed by MedicMobile, was enhanced to allow for bidirectional TB and COVID-19 screening and NCD screening. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $6,560,663 | ExpenseAmt |
| Grant | $3,736,744 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | Access EXPENDITURE USD 6,560,663 FIND and the Indonesian Ministry of Health (MoH) signed a memorandum of understanding (MoU) to expand access to essential diagnostics across 18,000 primary health centres throughout Indonesia, while enhancing pandemic surveillance and advancing diagnostics manufacturing in Indonesia. FIND entered a collaboration with the African Society for Laboratory Medicine (ASLM) and jointly launched the diagnostic network optimization sub-community of practice (DNO subCoP), under the overarching laboratory systems strengthening community of practice (LabCoP) initiative. Out of a target of 15 countries, 12 countries have ongoing or completed analyses using OptiDx-network optimization software co-developed by FIND to support resource planning for national laboratory systems-for TB, TB/HIV, and associated molecular testing. The capacity building of country teams in the use of OptiDx continues in several countries, including Cote d'Ivoire, India, and Zambia. Two strategic DNO analyses are underway, in Kenya and Pakistan, which will likely inform key priorities, including planning for Global Fund support, and integrated disease testing. FIND also developed an online DNO course, aimed at strategic decision-makers, in which 393 participants from 30 countries participated. DNO analyses in countries have focused on identifying gaps in testing capacity and strategies needed to expand testing in hard-to-reach areas. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $15,416,131 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $8,060,051 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $0 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $135,321,873 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | false | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | false | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | false | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | Yes (true) | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | false | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | false | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 0 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 132 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | false | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 10 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 10 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | false | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Form990 Provided To Gvrn Body | false | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| Own Website | Yes (X) | OwnWebsiteInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | NORMA TORRES COO | PersonNm |
| Phone | 0000000000 | PhoneNum |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 9 chemin des mines | AddressLine1Txt |
| City | geneva | CityNm |
| Country | SZ | CountryCd |
| Foreign Postal | 1202 | ForeignPostalCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part VII | Yes (X) | InfoInScheduleOPartVIIInd |
Form990 Part VII Section A Form990PartVIISectionAGrp (30 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd |
|---|---|---|---|---|---|---|---|---|---|
| William Rodriguez | |||||||||
| Chief Executive Officer | 40.0 | 0.0 | Yes (X) | $323,816 | $0 | $97,769 | |||
| SERGIO CARMONA | |||||||||
| CHIEF MEDICAL OFFICER | 40.0 | 0.0 | Yes (X) | $328,189 | $0 | $64,178 | |||
| LOUISA CHAUBERT | |||||||||
| Director of Finance | 40.0 | 0.0 | Yes (X) | $270,419 | $0 | $59,801 | |||
| Emma Jane Hannay | |||||||||
| Chief Access Officer | 40.0 | 0.0 | Yes (X) | $254,174 | $0 | $54,930 | |||
| Willo Brock start 922 | |||||||||
| VP,external Affairs | 40.0 | 0.0 | Yes (X) | $273,739 | $0 | $27,798 | |||
| Daniel Bausch | |||||||||
| sr. advisor, global health sec | 40.0 | 0.0 | $231,901 | $0 | $59,926 | Yes (X) | |||
| Marta Fernandez Suarez | |||||||||
| Chief Technology Officer | 40.0 | 0.0 | Yes (X) | $252,721 | $0 | $36,060 | |||
| MORTEN RUHWALD | |||||||||
| Director, TB Programme | 40.0 | 0.0 | $230,800 | $0 | $52,258 | Yes (X) | |||
| SHARON SAACKS | |||||||||
| DIRECTOR OF OPERATIONS | 40.0 | 0.0 | Yes (X) | $219,034 | $0 | $58,681 | |||
| BEATRICE MOUTON | |||||||||
| Director, Human Resources | 40.0 | 0.0 | $224,498 | $0 | $42,218 | Yes (X) | |||
| STEFANO ONGARELLO | |||||||||
| Director, Data Science | 40.0 | 0.0 | $207,805 | $0 | $48,938 | Yes (X) | |||
| SYLVAIN BIELER | |||||||||
| Senior Scientist | 40.0 | 0.0 | $213,699 | $0 | $40,291 | Yes (X) | |||
| Sanjay Sarin | |||||||||
| VP, ACCESS | 40.0 | 0.0 | $236,562 | $0 | $0 | Yes (X) | |||
| Aditi Srinivasan | |||||||||
| Director, Data Science | 40.0 | 0.0 | $203,387 | $0 | $30,550 | Yes (X) | |||
| Cassandra Kelly-Cirinostart922 | |||||||||
| VP; Health Programmes | 40.0 | 0.0 | Yes (X) | $76,930 | $0 | $20,146 | |||
| MARK KESSEL end 1122 | |||||||||
| CHAIRMAN OF THE BOARD | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| DANIEL ROBERT CAMUS | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| ANDREW JOHN JACK end 1122 | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| IONA KICKBUSH | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| CARLOS MOREL MEDICIS | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| MARCEL TANNER | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| SHEILA TLOU end 922 | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| MICHAEL WATSON end 922 | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| DAVID HEYMANN | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| GAO FU end 922 | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| KAMINENI SHOBANA | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| FRUTIGER CHRISTIAN | |||||||||
| BOARD MEMBER | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| Ayoade Alakija start 1122 | |||||||||
| Chairman of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| Soumya Swaminathanstart1122 | |||||||||
| Member of the Board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| Precious Matsoso start 1122 | |||||||||
| member of the board | 1.0 | 0.0 | $0 | $0 | $0 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,547,674 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $693,544 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 104 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | Province Or StateContractorAddress/ForeignAddress/ProvinceOrStateNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd |
|---|---|---|---|---|---|---|---|---|---|---|
| BioMerieux India Private Limited | ||||||||||
| 43A OKHLA PHASE-3 | NEW DELHI | 0 | IN | 110020 | Procurement | $3,510,601 | ||||
| Clinton Health Access Initiative | ||||||||||
| implement. partner | $2,044,503 | 383 Dorchester Ave Ste 400 | BOSTON | MA | 02127 | |||||
| Biomeme | ||||||||||
| R&D | $2,000,000 | 401 North Broad St Suite 222 | PHILADELPHIA | PA | 19108 | |||||
| Strategic Alliance mgmt Services Pv | ||||||||||
| NEW DELHI | DELHI | 0 | IN | 110065 | Procurement | $1,883,561 | ||||
| Division of Wits Health | ||||||||||
| 31 PRINCESS OF WALES TERRACE | JOHANNESBURG | 0 | SF | 2193 | Evaluation studies | $1,713,419 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 194 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $118,426,164 | GovernmentGrantsAmt |
| All Other Contributions | $24,565,345 | AllOtherContributionsAmt |
| Total Contributions | $142,991,509 | TotalContributionsAmt |
| Total Program Service Revenue | $0 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $961,319 | TotalRevenueColumnAmt |
| Exclusion | $961,319 | ExclusionAmt |
Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $0 | FundraisingGrossIncomeAmt |
| Fundraising Direct Expenses | $0 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $0 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $0 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Sales Of Inventory | $0 | GrossSalesOfInventoryAmt |
| Cost Of Goods Sold | $0 | CostOfGoodsSoldAmt |
Net Income Or Loss NetIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| COMMISSION ON TAX DEDUCTION | 900099 | $35,133 | $35,133 |
| OTHER INCOME | 900099 | $260,108 | $260,108 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $295,241 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $144,248,069 | TotalRevenueColumnAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $1,256,560 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $17,751,551 | TotalAmt |
| Program Services | $17,751,551 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $69,885,290 | TotalAmt |
| Program Services | $69,885,290 | ProgramServicesAmt |
Benefits To Members BenefitsToMembersGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,467,485 | TotalAmt |
| Program Services | $1,550,803 | ProgramServicesAmt |
| Management And General | $751,482 | ManagementAndGeneralAmt |
| Fundraising | $165,200 | FundraisingAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,627,720 | TotalAmt |
| Program Services | $12,300,226 | ProgramServicesAmt |
| Management And General | $3,095,379 | ManagementAndGeneralAmt |
| Fundraising | $232,115 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,381,101 | TotalAmt |
| Program Services | $1,041,902 | ProgramServicesAmt |
| Management And General | $329,343 | ManagementAndGeneralAmt |
| Fundraising | $9,856 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $925,049 | TotalAmt |
| Program Services | $553,348 | ProgramServicesAmt |
| Management And General | $362,165 | ManagementAndGeneralAmt |
| Fundraising | $9,536 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,514,784 | TotalAmt |
| Program Services | $1,173,415 | ProgramServicesAmt |
| Management And General | $317,325 | ManagementAndGeneralAmt |
| Fundraising | $24,044 | FundraisingAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,269,424 | TotalAmt |
| Program Services | $459,351 | ProgramServicesAmt |
| Management And General | $810,073 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $79,120 | TotalAmt |
| Program Services | $3,787 | ProgramServicesAmt |
| Management And General | $75,333 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $320,359 | TotalAmt |
| Program Services | $144,228 | ProgramServicesAmt |
| Management And General | $176,131 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,785 | TotalAmt |
| Program Services | $314 | ProgramServicesAmt |
| Management And General | $14,471 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,758,474 | TotalAmt |
| Program Services | $1,706,948 | ProgramServicesAmt |
| Management And General | $51,526 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,936,196 | TotalAmt |
| Program Services | $1,346,149 | ProgramServicesAmt |
| Management And General | $590,047 | ManagementAndGeneralAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $955,401 | TotalAmt |
| Program Services | $16,997 | ProgramServicesAmt |
| Management And General | $938,404 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,329,044 | TotalAmt |
| Program Services | $2,071,757 | ProgramServicesAmt |
| Management And General | $227,403 | ManagementAndGeneralAmt |
| Fundraising | $29,884 | FundraisingAmt |
Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $403,211 | TotalAmt |
| Program Services | $307,968 | ProgramServicesAmt |
| Management And General | $95,243 | ManagementAndGeneralAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Payments To Affiliates PaymentsToAffiliatesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,461 | TotalAmt |
| Management And General | $4,461 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $83,374 | TotalAmt |
| Program Services | $11,995 | ProgramServicesAmt |
| Management And General | $71,379 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| PROJECT CONTRACTORS | $19,812,475 | $18,427,047 | $1,050,154 | $335,274 |
| EQUIPMENT & SUPPLIES | $6,687,856 | $6,525,392 | $162,464 | |
| TRANSLATION & SPONSORSHIP | $69,170 | $43,405 | $25,765 | |
| FOREIGN EXCHANGE LOSSES | $910,168 | $910,168 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $146,186,498 | TotalAmt |
| Program Services | $135,321,873 | ProgramServicesAmt |
| Management And General | $10,058,716 | ManagementAndGeneralAmt |
| Fundraising | $805,909 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $22,817,170 | BOYAmt |
| EOY | $39,489,542 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $123,146,860 | BOYAmt |
| EOY | $81,401,662 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,930,408 | BOYAmt |
| EOY | $7,215,019 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $29,389,709 | BOYAmt |
| EOY | $9,166,796 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $76,320 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $76,320 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,461 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $218,509 | BOYAmt |
| EOY | $269,300 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $189,507,117 | BOYAmt |
| EOY | $137,542,319 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,499,354 | BOYAmt |
| EOY | $19,116,387 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $157,963,445 | BOYAmt |
| EOY | $96,758,415 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $167,462,799 | BOYAmt |
| EOY | $115,874,802 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,008,808 | BOYAmt |
| EOY | $12,607,693 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,035,510 | BOYAmt |
| EOY | $9,059,824 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $22,044,318 | BOYAmt |
| EOY | $21,667,517 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $189,507,117 | BOYAmt |
| EOY | $137,542,319 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | -$1,938,429 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $1,561,628 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consol And Sep Basis Fincl Stmt | Yes (X) | ConsolAndSepBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $59,513,727 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $55,842,142 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $97,561,319 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $108,984,293 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $142,991,509 | CurrentTaxYearAmt |
| Total | $464,892,990 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $59,513,727 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $55,842,142 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $97,561,319 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $108,984,293 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $142,991,509 | CurrentTaxYearAmt |
| Total | $464,892,990 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $53,028,383 | SubstantialContributorsTotAmt |
| Public Support Total170 | $411,864,607 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $340,946 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $314,122 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $189,810 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $624,209 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $961,319 | CurrentTaxYearAmt |
| Total | $2,430,406 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $447,040 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $585,117 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $461,449 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $423,638 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $295,241 | CurrentTaxYearAmt |
| Total | $2,212,485 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $469,535,881 | TotalSupportAmt |
| Public Support CY170 | 0.87717 | PublicSupportCY170Pct |
| Public Support PY170 | 0.80383 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE A, PART II, COLUMNS A-D | FormAndLineReferenceDesc |
| Explanation | The Support amounts reported in Columns A through D are reported on a consolidated basis. | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Art Public Exhibition Amounts | ArtPublicExhibitionAmountsGrp | |
| Held Works Art | HeldWorksArtGrp | |
| CY Minus3 Yr Endwmt Fund | CYMinus3YrEndwmtFundGrp | |
| CY Minus4 Yr Endwmt Fund | CYMinus4YrEndwmtFundGrp | |
| Land | LandGrp | |
| Buildings | BuildingsGrp | |
| Leasehold Improvements | LeaseholdImprovementsGrp |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $76,320 | OtherCostOrOtherBasisAmt |
| Depreciation | $76,320 | DepreciationAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Land Buildings | OtherLandBuildingsGrp | |
| Total Rev Etc Audited Fincl Stmt | $144,248,069 | TotalRevEtcAuditedFinclStmtAmt |
| Revenue Subtotal | $144,248,069 | RevenueSubtotalAmt |
| Total Revenue Per Form990 | $144,248,069 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $146,186,498 | TotExpnsEtcAuditedFinclStmtAmt |
| Expenses Subtotal | $146,186,498 | ExpensesSubtotalAmt |
| Total Expenses Per Form990 | $146,186,498 | TotalExpensesPerForm990Amt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| Sub-Saharan Africa | 1 | 4 | Program Services | SEE PART V | $24,292,340 |
| South Asia | 0 | 2 | Program Services | See Part V | $5,423,718 |
| East Asia and the Pacific | 1 | 7 | Program Services | See Part V | $22,172,364 |
| Europe (Including Iceland and Greenland) | 1 | 116 | Program Services | See Part V | $63,637,622 |
| South America | 0 | 0 | Program Services | See Part V | $3,774,608 |
| North America | 0 | 0 | Program Services | See Part V | $676,041 |
| Russia and the Newly Independent States | 0 | 0 | Program Services | See Part V | $1,246,649 |
| Middle East and North Africa | 0 | 0 | Program Services | See Part V | $251,485 |
| Central America and the Caribbean | 0 | 0 | Program Services | See Part V | $805,287 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 3 | SubtotalOfficesCnt |
| Subtotal Employees | 129 | SubtotalEmployeesCnt |
| Total Office | 3 | TotalOfficeCnt |
| Total Employee | 129 | TotalEmployeeCnt |
| Subtotal Spent | $122,280,114 | SubtotalSpentAmt |
| Total Spent | $122,280,114 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (9 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Description Of Non Cash AsstDescriptionOfNonCashAsstTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|---|
| Sub-Saharan Africa | Diagnostics | $17,684,107 | ELEC FD TRAN | N/A | N/A |
| South Asia | Diagnostics | $1,937,978 | ELEC FD TRAN | N/A | N/A |
| East Asia and the Pacific | Diagnostics | $18,066,911 | ELEC FD TRAN | N/A | N/A |
| Europe (Including Iceland and Greenland) | Diagnostics | $26,938,776 | ELEC FD TRAN | N/A | N/A |
| South America | Diagnostics | $3,331,496 | ELEC FD TRAN | N/A | N/A |
| North America | Diagnostics | $215,853 | ELEC FD TRAN | N/A | N/A |
| Russia and the Newly Independent States | Diagnostics | $903,809 | ELEC FD TRAN | N/A | N/A |
| Middle East and North Africa | Diagnostics | $43,893 | ELEC FD TRAN | N/A | N/A |
| Central America and the Caribbean | Diagnostics | $762,468 | ELEC FD TRAN | N/A | N/A |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 131 | Total501c3OrgCnt |
| Total Other Org | 217 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE F, PART I, LINE 2: | Contracts are given for research and development of new tools for the diagnosis of infectious diseases. Except for the initial advance payments, payments are conditional upon achievement of milestones or deliverables through the period of the contract as evidenced in contractually specified reports. In addition to the regular reports, program managers monitor progress with regular communications and physical and virtual site visits. Finally, most major grants are subject to annual donor audits which are in addition to the statutory audit. |
| Schedule F, Part I, Line 3, Column E: PROGRAM SERVICE DESCRIPTION | In each region, FIND conducted the following program services - Laboratory Strengthening Evaluation Work. |
| Schedule F, Part I, Line 3, Column F: | all expenditures are reported under the accrual accounting method. |
| Schedule F, Part II, Line 2: | Due to the high volume of organizations that were provided assistance from FIND during 2022, it would be difficult for FIND to list each organizations and grant amount individually on Schedule F, Part II. Therefore, FIND has listed the total amount of assistance provided for region in 2022. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (33 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Cash GrantCashGrantAmt | Valuation Method UsedValuationMethodUsedDesc | Non Cash AssistanceNonCashAssistanceDesc | Purpose Of GrantPurposeOfGrantTxt | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|---|
| Exponent | ||||||||||
| 1075 Worcester Street | natick | MA | 01760 | $122,200 | N/A | N/A | Technical Dossier review for submission of a regulatory package to the World Health Organization "WHO" | |||
| Rutgers The State University of New Jersey | ||||||||||
| 65 Davidson Rd | piscataway | NJ | 088545602 | $22,242 | N/A | N/A | TB diagnostics including sample preparation and novel molecular tests for diagnosis | 226001086 | 501(C)(3) | |
| The Center for Affordable Health | ||||||||||
| 4938 Hampden Ln 186 | bethesda | MD | 20814 | $9,936 | N/A | N/A | To provide material for publication | |||
| The Regents of the University of california | ||||||||||
| 9500 Gilman Drive | la jolla | CA | 920630602 | $66,493 | N/A | N/A | Consulting services and blood culture due diligence support | 956006144 | 501(C)(3) | |
| University of Washington | ||||||||||
| 4333 Brooklyn Avenue NE Box 359472 | seattle | WA | 98195 | $27,022 | N/A | N/A | assessment of HCV self testing | 916001537 | 501(C)(3) | |
| Biomedical Research Institute | ||||||||||
| 9410 KEY WEST AVENUE | ROCKVILLE | MD | 20850 | $76,000 | N/A | N/A | Supply of Schistomiasis parasites to FIND partner sites. | 362229561 | 501(C)(3) | |
| Boston Children's Hospital | ||||||||||
| 300 LONGOOD AVE | BOSTON | MA | 02215 | $42,617 | N/A | N/A | Research agreement for cross-cutting diseases | 042774441 | 501(C)(3) | |
| Boston University | ||||||||||
| 25 BUICK ST 2ND FL | BOSTON | MA | 02215 | $655,323 | N/A | N/A | Sponsored Research | 042103547 | 501(C)(3) | |
| BroadInstitute | ||||||||||
| 415MainStreet | Cambridge | MA | 02142 | $190,400 | n/a | n/a | Developmentofarapide,point-of carediagnosticforhighsensitivitydetectionof Tuberculosis | 263428781 | 501(C)(3) | |
| CHAI-ClintonHealthAccessInitiationInc | ||||||||||
| 383DorchesterAvenue | Boston | MA | 02127 | $2,007,458 | n/a | n/a | TosupportTBeliminationefforts | 271414646 | 501(C)(3) | suite400 |
| ColumbiaUniversity | ||||||||||
| 630West168thStreet | new york | NY | 10032 | $792,000 | n/a | n/a | ImplementationofcovidagRDTsinSouthSudan | 135598093 | 501(C)(3) | |
| DiagnosticConsultingNetworkInc | ||||||||||
| 6354CorteDelAbeto | Carlsbad | CA | 92011 | $854,249 | n/a | n/a | Developmentofdiagnostictests | 205531959 | ||
| DimagiInc | ||||||||||
| 585MassachusettsAve | Cambridge | MA | 02139 | $252,335 | n/a | n/a | Productionofmobilephoneappsthatcollectsdata fromrapidvitrodiagnostictestandthatcanaid anRDTuserininterpretingthetestresults | 830343298 | ||
| Drugs&DiagnosticsforTropicalDiseases | ||||||||||
| 4898RonsonCt | SanDiego | CA | 92111 | $27,969 | n/a | n/a | Developmentandcommercialisationofdiagnotic tests | 274482027 | 501(C)(3) | |
| ManagementSciencesforHealth | ||||||||||
| 784MemorialDr | cambridge | MA | 02139 | $621,481 | n/a | n/a | Undertake a project in the field of in vitro diagnostics and COVID | |||
| Transnational TechnologiesInc | ||||||||||
| 7324AuburnwoodLane | Windermere | FL | 34786 | $3,200,000 | n/a | n/a | Supportmanufacturingandcommercializationof antigenrdtforcovid | |||
| UniversityofNorthCarolina | ||||||||||
| 104AirportDr | ChapelHill | NC | 275991350 | $644,191 | n/a | n/a | Laboratorystrengtheningtosupportclinicalcare andresearch | 566001393 | 501(C)(3) | STE2200 |
| UniversityofAlabama | ||||||||||
| 70120thStS | Birmingham | AL | 352940111 | $119,140 | n/a | n/a | Studytosupportclinicalperformanceevaluation ofGonorrhoea | 636005396 | 501(C)(3) | AB1170 |
| WHO-PAHO | ||||||||||
| RegOfficeoftheWHO | Washington | DC | 20037 | $2,275,676 | n/a | n/a | Scaling-uptheuseofcovidantigenrapiddiagnost ic tests in Americas testsinAmericas testsinAmericas | 501(C)(3) | ||
| WolfGreenfieldandSacksPC | ||||||||||
| 600AtlanticAvenue | Boston | MA | 022102206 | $211,332 | n/a | n/a | IPlandscapestudydirectedtothedetectionof NGAL/LCN-2biomarkers | |||
| ADVENTION BUSINESS PARTNERS INC | ||||||||||
| 10 EAST 40TH STREET SUITE 3310 | NEW YORK | NY | 10016 | $62,507 | N/A | N/A | To establish a framework by which to assess cost of goods sold (COGS), including reagent components, cost drivers, and margins for critical sequencing reagents | |||
| Audere | ||||||||||
| 1191 2nd Ave Ste 450 | Seattle | WA | 98101 | $147,704 | N/A | N/A | Develop and make available digital tools for lay users to promote proper performance of CV-19 antigen RDTs and reporting of the results (ST project) | |||
| Biomeme | ||||||||||
| 1015 Chestnut St Suite 1401 | Philadelphia | PA | 19107 | $4,015,000 | N/A | N/A | Development of diagnostic tests | |||
| DetectoGen Inc | ||||||||||
| 5 Jacob Amsden Road | Westborough | MA | 01581 | $5,368 | N/A | N/A | Supply of research material (antibodies) | |||
| Elizabeth Glaser Pediatric Aids Foundation | ||||||||||
| 1140 Connecticut Ave NW Ste 200 | Washington | DC | 20036 | $793,500 | N/A | N/A | Evaluation of Antigen Rapid Diagnostic Tests | |||
| Harvard College | ||||||||||
| 1350 Massachusetts Avenue Suite 72 | Cambridge | MA | 02138 | $32,849 | N/A | N/A | Project agreement with Harvard for Seq&Treat mutations catalogue work | 042103580 | 501(C)(3) | |
| International Rescue Committee Inc | ||||||||||
| 122 E 42nd St | New York | NY | 10168 | $224,051 | N/A | N/A | Supporting the use of rapid diagnostic tests for COVID-19 in humanitarian settings | |||
| Perkinelmer Health Sciences Inc | ||||||||||
| 710 Bridgeport Ave | Shelton | CT | 06484 | $300,000 | N/A | N/A | Develop and register with SRAs a Product that complies with the product requirements for commercialization | |||
| Program Appropriate Tech in Health | ||||||||||
| 2201 Westlake Avenue Suite 200 | Seattlle | WA | 98121 | $312,583 | N/A | N/A | Genomics trainings. Supporting the Africa CDC Workforce Development Effort for Pathogen Genomic Surveillance | 911157127 | 501(C)(3) | |
| Sherlock Biosciences Inc | ||||||||||
| 200 Talcott Ave | Watertown | MA | 02472 | $202,000 | N/A | N/A | COVID 19 molecular platform evaluation | |||
| Sonavi Labs Inc | ||||||||||
| 1100 Wicomico St Suite 600 | Baltimore | MD | 21230 | $6,800 | N/A | N/A | Digital stethoscope for TB | |||
| University of Massachusetts Amherst | ||||||||||
| 813 North Pleasant | StAmherst | MA | 01003 | $25,000 | N/A | N/A | Material transfer agreement | 542084125 | 501(C)(3) | |
| Vera Solutions | ||||||||||
| 444 Manhattan Ave Suite 4C | New York | NY | 10026 | $5,350 | N/A | N/A | Support on Salesforce tool utilization | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 16 | Total501c3OrgCnt |
| Total Other Org | 17 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | schedule f, Part I, Line 2 | FormAndLineReferenceDesc |
| Explanation | Contracts are given for research and development of new tools for the diagnosis of infectious diseases. Except for the initial advance payments are conditional upon achievement of milestones or deliverables through the period of the contract evidenced in contractually specified reports. In addition to the regular reports, program managers monitor progress with regular communications and physical/virtual site visits. Finally, most major grants are subject to annual audits which are in addition to the statutory audit. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Severance Payment | false | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| William Rodriguez | ||||||||||||
| Chief Executive Officer | $308,730 | $0 | $15,086 | $0 | $0 | $0 | $67,143 | $0 | $30,626 | $0 | $421,585 | $0 |
| SHARON SAACKS | ||||||||||||
| DIRECTOR OF OPERATIONS | $210,467 | $0 | $8,567 | $0 | $0 | $0 | $47,288 | $0 | $11,393 | $0 | $277,715 | $0 |
| LOUISA CHAUBERT | ||||||||||||
| Director of Finance | $261,852 | $0 | $8,567 | $0 | $0 | $0 | $53,506 | $0 | $6,295 | $0 | $330,220 | $0 |
| Willo Brock start 922 | ||||||||||||
| VP,external Affairs | $262,155 | $0 | $11,584 | $0 | $0 | $0 | $22,213 | $0 | $5,585 | $0 | $301,537 | $0 |
| SERGIO CARMONA | ||||||||||||
| CHIEF MEDICAL OFFICER | $319,622 | $0 | $8,567 | $0 | $0 | $0 | $60,016 | $0 | $4,162 | $0 | $392,367 | $0 |
| BEATRICE MOUTON | ||||||||||||
| Director, Human Resources | $215,931 | $0 | $8,567 | $0 | $0 | $0 | $42,218 | $0 | $0 | $0 | $266,716 | $0 |
| STEFANO ONGARELLO | ||||||||||||
| Director, Data Science | $201,647 | $0 | $6,158 | $0 | $0 | $0 | $39,505 | $0 | $9,433 | $0 | $256,743 | $0 |
| MORTEN RUHWALD | ||||||||||||
| Director, TB Programme | $219,431 | $0 | $11,369 | $0 | $0 | $0 | $42,050 | $0 | $10,208 | $0 | $283,058 | $0 |
| SYLVAIN BIELER | ||||||||||||
| Senior Scientist | $205,385 | $0 | $8,314 | $0 | $0 | $0 | $40,291 | $0 | $0 | $0 | $253,990 | $0 |
| Emma Jane Hannay | ||||||||||||
| Chief Access Officer | $245,553 | $0 | $8,621 | $0 | $0 | $0 | $54,930 | $0 | $0 | $0 | $309,104 | $0 |
| Marta Fernandez Suarez | ||||||||||||
| Chief Technology Officer | $242,005 | $0 | $10,716 | $0 | $0 | $0 | $20,461 | $0 | $15,599 | $0 | $288,781 | $0 |
| Sanjay Sarin | ||||||||||||
| VP, ACCESS | $228,000 | $0 | $8,562 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $236,562 | $0 |
| Daniel Bausch | ||||||||||||
| sr. advisor, global health sec | $223,334 | $0 | $8,567 | $0 | $0 | $0 | $48,289 | $0 | $11,637 | $0 | $291,827 | $0 |
| Aditi Srinivasan | ||||||||||||
| Director, Data Science | $198,511 | $0 | $4,876 | $0 | $0 | $0 | $30,550 | $0 | $0 | $0 | $233,937 | $0 |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, BOX E: | THE ORGANIZATION'S TELEPHONE NUMBER IS +41 (22) 710 05 90. |
| FORM 990, PART III, LINE 4D: | Antimicrobial resistance (AMR) FIND completed the first clinical evaluation of a gonorrhoea RDT (developed with DCN Dx, USA) in patients with signs and symptoms of a sexually transmitted infection (STI) in South Africa, showing a sensitivity of 91% and specificity of 96.3%, higher than the minimal requirements set out in the WHO TPP. FIND supported 8 products (4 IVDs and 4 digital tools) across various stages of diagnostic product life cycle. In Nepal, FIND worked with government agencies to develop an AMR database, which represents the single most comprehensive repository in the country, with data from both the human health and animal health sectors on the extent of AMR in the country. In Kenya, FIND supported the National Antimicrobial Stewardship Interagency Committee (NASIC) in strengthening the existing AMR surveillance system. FIND participated in several G20 meetings, in sessions on AMR/One Health and the role of public-private partnerships in responding to future health threats. Clinical studies as part of the FIND AMR Diagnostic Use Accelerator have now been completed in Burkina Faso (IRSS-CRUN), Ghana (DHRC), India (ICMR), Nepal (OUCRU) and Uganda (IDRC). The project has been conducted in two phases (Phase I: pre-COVID-19; Phase II: including COVID-19). By the end of 2022, both phases were in the completion stages, with the submission for publication of Phase 1 results forming a special supplement (ten papers) in the journal Clinical Infectious Diseases in mid-2023. The results of these studies will contribute to evidence needed to inform guidance and polices that highlight the importance of diagnostics to optimize the use of antibiotics. Pandemic Threats In June 2022, FIND signed a multiyear partnership with Gavi, the Vaccine Alliance, to support new diagnostic tests for the surveillance of vaccine-preventable diseases, addressing a major gap in Gavi's immunization programmes. FIND will engage WHO to create or update TPPs for diagnostic tests for cholera, typhoid, meningitis and yellow fever; support test evaluation; and provide technical assistance and guidance to WHO expert committees on the deployment and use of improved test kits for these four diseases. FIND will join Gavi, Unicef and WHO to establish mechanisms to improve access to these tests, enhancing Gavi's vaccine programmes. In 2022, FIND supported 27 products (18 IVDs and 9 digital tools for COVID-19, Lassa fever, Marburg virus, yellow fever, multi-disease platforms) across various stages of diagnostic product life cycle including 17 IVDs and 5 digital tools in the development phases. For capacity strengthening for Nigeria's Lassa fever preparedness and response, FIND activated 9 new laboratories, and more than 2000 well-characterized blood samples are now available for Lassa fever research. FIND added 3599 Lassa fever samples to the biobank in Nigeria. Access TB India In 2022 in India, FIND established and handed over an additional 11 BSL-3 TB culture and drug-susceptibility testing (DST) laboratories, bringing the total number of TB laboratories under the national TB Programme (NTP) across the country to 81 (all established by FIND). These laboratories conducted over 375,000 DSTs and diagnosed ~65,000 drug resistant TB cases during the year. FIND also supported 17 culture and DST laboratories in achieving and maintaining ISO 15189 certification, and mentored another 15 laboratories towards achieving the certification. FIND supported the NTP in establishing an EQA mechanism for Xpert MTB/RIF and Truenat sites across the country. During 2022, 1280 Xpert and 840 Truenat sites participated in EQA with 95% Xpert and over 85% Truenat sites achieving satisfactory results. Through the project JEET (Joint Effort for Elimination of TB), FIND facilitated screening of over 170,000 household contacts for TB infection, enabling nearly 112,000 people to initiate TB preventive treatment in 22 districts across four states in the country. FIND provided technical assistance and capacity building for diagnosis management of drug-resistant TB in children. Situational and gap analysis was conducted in collaboration with NTP in three large states (Delhi, Maharashtra and Madhya Pradesh) engaging paediatric drug-resistant TB experts and state-specific roadmaps for improving diagnosis and management of paediatric drug-resistant TB cases were developed. Fever and Malaria FIND and WHO jointly developed a TPP for rapid diagnostic test (RDT) readers, as a companion tool for RDTs for malaria, COVID-19 and other disease areas, to promote more consistent and accurate test performance, interpretation and reporting. These RDT readers can take the form of dedicated hardware instruments or of applications on mobile phones and tablets, for professional use or self-testing and as a medical device or a non-medical data capture tool. FIND supported 5 products (3 IVDs and 2 digital tools) across various stages of diagnostic product life cycle, including 3 IVDs and 1 digital tool in the development phases. FIND studies as part of the Malaria Innovation Platform enrolled 3533 individuals with malaria in Indonesia, Peru and Sudan, nearly completing enrolment for the evaluation of five new non-HRP2 (histidine-rich protein 2) RDTs from two developers, to address the threat of inaccurate malaria RDT results caused by gene deletions in the malaria parasite (known as pfhrp2 deletions). The results will be included in WHO PQ dossiers. Neglected tropical diseases (NTDs) In April 2022, based on the RDT and diagnostic strategy led by FIND known as "Trypa-No!", WHO confirmed elimination of the gambiense form of human African trypanosomiasis (HAT, or "sleeping sickness") in Uganda. With FIND's ongoing support, a request for validation of HAT elimination in Chad has also been submitted. FIND supported 8 IVDs (for Buruli ulcer, Chagas disease, HAT, schistosomiasis, leishmaniasis) across various stages of diagnostic product life cycle, including 7 IVDs in the development phases. FIND has been supporting implementation projects to improve visceral leishmaniasis (VL) diagnosis in Kenya, by strengthening healthcare facilities to diagnose the disease through a combination of clinical signs and RDTs, backed up by strategic referral centres to confirm RDT-negative suspect cases using direct agglutination test (DAT). This strategy, supplemented with VL awareness campaigns among local communities, has allowed patients access to prompt diagnosis and treatment as close as possible to their place of residence. FIND's activities began in Turkana County in 2016 and have since been progressively extended to all 11 VL-endemic counties in Kenya. Since 2020, 200 health workers have been trained. More than 900 community volunteers have also been trained to support the identification of suspected cases identification and referral to health facilities. Knowledge of VL in the endemic population and access to diagnosis and treatment has improved, and the case fatality rate has declined, from more than 2% to less than the 1% elimination threshold. The time to diagnosis and treatment following the onset of symptoms has also reduced. Non-communicable diseases (NCDs) FIND supported the development of 2 IVDs (POC liver test platform and liver function RDT) in 2022. As part of market innovation efforts, FIND addressed the affordability and quality of existing diabetes diagnostics. FIND negotiated price reductions with three haemoglobin A1c (HbA1c) POC test manufacturers, from US$7 to US$3.50, for blood glucose meter/strips. Orders for 8.3 million glucose test strips and 11,000 blood glucose meters were operationalized for products under long-term agreements (LTAs) with FIND at preferential prices and in four countries: Cambodia, Kenya, Palestine, and Rwanda. FIND identified a price for continuous glucose monitors (CGMs), which was considered cost-effective/affordable across five countries. Current global pricing for a CGM is approximately US$65. Based on FIND analysis, recommended global pricing for a CGM to be considered cost-effective is US$15, representing a 77% cost-reduction. This information is being used to drive negotiations with suppliers around global CGM pricing for the countries that FIND supports. Women's health In 2022, FIND laid the groundwork for a new programme focused on women's health. In Kenya and Viet Nam, FIND is supporting the ministries of health to introduce or scale-up the availability of selected POC tests at the primary care level, as part of informing best practices for scaling up access to essential diagnostics in primary healthcare. In Kenya, FIND is supporting basic screening tests prescribed for pregnant women attending antenatal care visits, while in Viet Nam the selected POC tests prioritize women's and children's health, as well as common respiratory illnesses. |
| Form 990, Part V, Line 2a and Part VII, Section A | Individuals employed by FIND are not US residents or US employees. Information pertaining to the number of employees and employee compensation is provided using the best information available from equivalent W-2 & W-3 forms for the various countries in which FIND employs individuals. |
| FORM 990, PART VI, LINE 11B: | FORM 990 REVIEW PROCESS The Form 990 is prepared by an independent accounting firm and reviewed by the director of finance. Once approved by the director of finance, the Form 990 is also reviewed by the CEO. Additionally, in 2021, FIND participated in a benchmarking exercise with peer of finance, the Form 990 is also reviewed by the CEO. Additionally, in 2021, FIND participated in a benchmarking exercise with peer organization to ensure consistency of treatment of various items on Form 990. |
| FORM 990, PART VI, LINE 12C: | FINDs conflict of interest policy requires directors, officers and key employees, all other staff members, board members, consultants and partners to disclose actual or potential conflicts of interest when they arise. The person or company is also required to recuse themselves from any decision making. |
| FORM 990, PART VI, LINES 15A & 15B: | COMPENSATION REVIEW A review by an independent consultant of the CEO's remuneration package was done by the Board and forms the basis of a written employment contract. Remuneration terms for officers and key employees are based on market rates for similar positions in specific locations. The Compensation Committee. This benchmarking is done against an independent report which presents data collected for similar organizations and this exercise is done every 3 years. Salaries for all staff are available to the Board and Compensation Committee. However, the salaries of the C-suite and other key staff are approved by the Compensation Committee. |
| FORM 990, PART VI, LINES 19: | AVAILABILITY OF GOVERNING DOCUMENTS TO THE PUBLIC Upon request FIND's governing documents (Statutes and By-Laws) Conflict of Interest policy and Financial Statements are available for inspection at FIND's offices in Geneva, Switzerland. |
| FORM 990, PART VI, LINE 20: | Books in care of phone number the telephone number of the person who possesses the books and records is +41 (22) 710 0590 |
| FORM 990, PART XI, LINE 9 | prior period adjustment - restatement of grant treatment in audited financial statements - $1,561,628 |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Province Or StateForeignAddress/ProvinceOrStateNm |
|---|---|---|---|---|---|---|---|---|---|---|
| FIND INDIA | ||||||||||
| FLAT NO 8 9TH FL 17 BARAKHAMBA RD | NEW DELHI | IN | 110001 | PROGRAM SVCS | IN | n/a | n/a | FIND SWISS | Yes (true) | |
| FIND DX NPC | ||||||||||
| 89 ROODEBLOEM ROAD | WOODSTOCK | SF | PROGRAM SVCS | SF | n/a | n/a | FIND SWISS | Yes (true) | CAPE TOWN | |
| FIND DX KENYA | ||||||||||
| OFF MBAGATHI RD PO BOX 54840 | NAIROBI | KE | 00200 | PROGRAM SVCS | KE | n/a | n/a | FIND SWISS | Yes (true) | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | false | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | false | SharingOfFacilitiesInd |
| Paid Employees Sharing | false | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | Yes (true) | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (3 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| FIND DX Kenya | ||
| r | $838,823 | fmv |
| FIND DX NPC | ||
| r | $443,848 | fmv |
| FIND India | ||
| r | $381,265 | fmv |